Evidence map›Paper›PMID 37344720›Full record

ArticleAging clinical and experimental research2023

Comparing the prognostic value of the old and new sarcopenia criteria from the Asian Working Group on Sarcopenia in older adults with type 2 diabetes: Which set is more appropriate?

Xin Ye, Fengning Chuan, Ying Li, Shuang Kang, Wenqing Tian, Mei Mei, Kun Liao, Lilin Gong, Bo Zhou

Abstract read
PubMed Publisher
In one paragraph

Article in Aging clinical and experimental research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Xin Ye *Department of Endocrinology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Fengning Chuan *Department of Endocrinology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Ying LiDepartment of Endocrinology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Shuang KangDepartment of Endocrinology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Wenqing TianDepartment of Endocrinology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Mei MeiDepartment of Endocrinology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Kun LiaoDepartment of Endocrinology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Lilin GongDepartment of Endocrinology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Bo ZhouDepartment of Endocrinology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China. zhoubo915@126.com.
First Affiliated Hospital of Chongqing Medical University · CNChongqing Medical University · CNChongqing University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThis study aimed to compare the prevalence of sarcopenia according to the old and new Asian Working Group on Sarcopenia (AWGS) operational criteria and explore the effects of sarcopenia on adverse outcomes in older adults with type 2 diabetes (T2D).

methodsA total of 386 patients with T2D aged ≥ 60 years were recruited in retrospective cohort study. Sarcopenia was assessed with different versions of the AWGS consensus, including the AWGS2014, AWGS2019H (muscle mass adjusted for height), and AWGS2019B (muscle mass adjusted for body mass index). The median follow-up period was 47 months. The composite primary endpoint was the first occurrence of cardiovascular disease (CVD), fragility fracture, and all-cause mortality and the secondary outcomes included the three separate components of the primary outcome.

resultsIn this study, the prevalence of sarcopenia under different criteria was significantly different, with AWGS2019H having the highest prevalence of 31.3%. The agreement among sarcopenia criteria was unsatisfactory. By Cox regression analysis, all three AWGS definitions of sarcopenia were associated with the composite outcome of all-cause mortality, fracture and CVD (hazard ratio [HR], 2.69 vs. HR, 2.63; vs. HR, 2.23; model 3). Further exploratory analysis, sarcopenia defined by the AWGS2019H criteria was an independent risk factor for death, incident CVD, and fractures. While AWGS2014 criteria was an increased risk factor of death and CVD. The AWGS2019B criteria were only associated with incident fractures.

conclusionAll three AWGS definitions of sarcopenia were associated the composite primary endpoint. Additionally, the AWGS2019H criteria may be a better independent risk factor for negative health outcomes.

Indexed as

Cardiovascular DiseasesDiabetes Mellitus, Type 2Fractures, BoneSarcopeniaAgedHand StrengthHumansPrevalencePrognosisRetrospective StudiesGuidelines comparisonMortalityPrognosisSarcopeniaType 2 diabetes

Identifiers

PMID37344720
OpenAlexW4381597850

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.